Overexpression of fractalkine and its histopathological characteristics in primary pterygium
- 28 Downloads
This study aimed to evaluate the differences in the expressions of fractalkine in normal bulbar conjunctiva and primary pterygium tissues.
The study included 48 patients who had been operated on for primary pterygium. Histopathologically, the presence of epithelial atypia, epithelial hyperplasia, goblet cell hyperplasia, epithelial lymphocytic exocytosis, stromal inflammation, mast cell count, and stromal vascularity were evaluated in the primary pterygium tissues. An immunohistochemical fractalkine stain was applied to the primary pterygium tissue samples and normal bulbar conjunctival tissue samples.
Primary pterygium and normal bulbar conjunctival tissue samples were histopathologically analyzed. Epithelial atypia, epithelial hyperplasia, epithelial lymphocytic exocytosis, stromal inflammation, stromal vascularity, and mast cell count were found to be significantly higher in the primary pterygium (p = 0.001, p = 0.002, p = 0.024, p = 0.007, p = 0.024, and p = 0.013, respectively). When evaluated in terms of fractalkine expression, the epithelial, vascular endothelial, and inflammatory cells were significantly higher in the primary pterygium (p ≤ 0.001, p = 0.002, p = 0.001, respectively). Moreover, compared to the normal bulbar conjunctiva, Ki-67 expression was significantly higher in the primary pterygium tissue samples.
Fractalkine might play a key role in the etiopathogenesis of pterygium. Fractalkine may be important in developing new treatment approaches.
KeywordsPterygium Immunhystochemistry Fractalkine Ki-67 Conjunctiva Histopathology
The study was supported by Scientific Investigations Foundation of Balikesir University (Project no: BAP. 2018/159).
This study was funded by Scientific Investigations Foundation of Balikesir University (grant number 2018/159).
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (ethical committee of Balikesir University Medical Faculty (Date: 05.09.2018/reference no: 2018/144)) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 4.Golu T, Mogoanta L, Streba CT et al (2011) Pterygium: histological and immunohistochemical aspects. Romanian J Morphol Embryol 52:153–158Google Scholar
- 9.Usta A, Turan G, Sancakli Usta C et al (2018) Placental fractalkine immunoreactivity in preeclampsia and its correlation with histopathological changes in the placenta and adverse pregnancy outcomes. J Matern Fetal Neonatal Med 10:1–10. https://doi.org/10.1080/14767058.2018.1505854 CrossRefGoogle Scholar
- 10.Ruth JH, Volin MV, Haines GK et al (2001) Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 44:1568–1581. https://doi.org/10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1 CrossRefPubMedGoogle Scholar
- 12.Sindhu S, Akhter N, Arefanian H et al (2017) Increased circulatory levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes. J Diabetes Metab Disord 16:15. https://doi.org/10.1186/s40200-017-0297-3 CrossRefPubMedPubMedCentralGoogle Scholar